Partner Headlines - NPSP

  1. Benzinga's M&A Chatter for Wednesday December 17, 2014

    Benzinga
  2. NPS Pharmaceuticals Spikes 19% Amid Shire Bid Report

    Benzinga
  3. Morning Market Losers

    Benzinga
  4. Benzinga's Top #PreMarket Losers

    Benzinga
  5. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  6. Benzinga's Weekend M&A Chatter

    Benzinga
  7. Technology Stocks Down As Rest Of The Market Starts Week Flat

    Benzinga
  8. Terex Falls After Lowered Earnings Forecast; Avanir Pharmaceuticals ...

    Benzinga
  9. NASDAQ Tumbles 1.1%; Alere Shares Surge Following Proposed $46/Share ...

    Benzinga
  10. Markets Fall; Cognizant To Acquire TriZetto For $2.7 Billion

    Benzinga
  11. Morning Market Losers

    Benzinga
  12. Benzinga's Top #PreMarket Losers

    Benzinga
  13. US Stock Futures Flat Ahead Of Economic Data

    Benzinga
  14. NPS Pharma Stock Trading Halted Today; FDA Advisory Committee ...

    Benzinga
  15. FDA says NPS drug is effective

    IBD
  16. Stocks Gain As Oil, Euro Continue Sharp Sell Off

    Benzinga
  17. Lands' End Jumps On Strong Quarterly Earnings; GT Advanced Technologies ...

    Benzinga
  18. U.S. Stocks Rise; Palo Alto Networks Shares Surge On Upbeat Revenue

    Benzinga
  19. Markets Edge Lower; Krispy Kreme Doughnuts Profit Misses Estimates

    Benzinga
  20. Benzinga's Volume Movers

    Benzinga
  21. Morning Market Movers

    Benzinga
  22. FDA Posts Briefing Materials For Advisory Committee Meeting ...

    Benzinga
  23. NPS Pharma Initiates Phase 2a Study Of NPSP795 In Adult Patients ...

    Benzinga
  24. Valeant Goes For Allergan; Analyst Touts Shire Option

    IBD
  25. Mid-Afternoon Market Update: Markets Turn Back As SolarCity Hangs ...

    Benzinga
  26. Mid-Day Market Update: Keurig Green Mountain Jumps On Upbeat ...

    Benzinga
  27. Mid-Morning Market Update: Markets Gain; Wendy's Profit Beats ...

    Benzinga
  28. Morning Market Losers

    Benzinga
  29. UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals ...

    Benzinga
  30. Benzinga's Top Initiations

    Benzinga
  31. UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

    Benzinga
  32. NPS Pharma Finds Big Success In Tiny Markets

    IBD
  33. Market Wrap For January 8: Fed Minutes Released

    Benzinga
  34. NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara ...

    Benzinga
  35. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  36. Mid-Afternoon Market Update: Markets Mixed as Tesla Shares Remain ...

    Benzinga
  37. NPS Pharma Says Data from STEPS 2 Trial of Gattex Supports Long-Term ...

    Benzinga
  38. Mid-Afternoon Market Update: Markets Green as Spirit Airlines ...

    Benzinga
  39. Mid-Day Market Update: Micron Shares Tumble On Downbeat Profit; ...

    Benzinga
  40. Mid-Morning Market Update: Markets Rise; JPMorgan Posts Upbeat ...

    Benzinga
  41. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  42. NPS Pharma Says 53% of Natpara-Treated Patients Achieved Primary ...

    Benzinga
  43. UPDATE: Bank of America Initiates Coverage on NPS Pharmaceuticals ...

    Benzinga
  44. Benzinga's Top Initiations

    Benzinga
  45. NPS Pharma Says sNDA Submitted for Gattex STEPS 2 Data, Shows ...

    Benzinga
  46. Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN

    GuruFocus
  47. UPDATE: J.P. Morgan Initiates Coverage on NPS Pharmaceuticals ...

    Benzinga
  48. Benzinga's Top Initiations

    Benzinga
  49. UPDATE: Oppenheimer Raises PT on NPS Pharmaceuticals Following ...

    Benzinga
  50. Market Wrap for Friday, August 9: Stocks Close Lower To End Week

    Benzinga
  51. NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth ...

    YCharts
  52. You Can Expect More Insider Trading in Pharma Stocks: Here's ...

    YCharts
  53. FDA Approves NPS Gattex for Injection for Some SBS Patients

    Benzinga
  54. NPS Pharma Shares Moving Lower Amid FDA Approval of Gattex

    Benzinga
  55. NPS Pharma Publishes Pivotal Phase 3 Study of Gattex in Short ...

    Benzinga
  56. NPS Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  57. Benzinga Mid-Afternoon Market Update

    Benzinga
  58. Benzinga Mid-Day Market Update

    Benzinga
  59. Benzinga Mid-Morning Market Update

    Benzinga
  60. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT ...

    Benzinga
  61. FDA Advisory Committee Unanimously Recommends Approval of Gattex® ...

    Benzinga
  62. Benzinga Mid-Day Market Update

    Benzinga
  63. Benzinga Mid-Afternoon Market Update

    Benzinga
  64. Benzinga Mid-Morning Market Update

    Benzinga
  65. UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight ...

    Benzinga
  66. Benzinga's Top Pre-Market Gainers

    Benzinga
  67. NPS Pharma Expects to File Natpara BLA in Mid 2013

    Benzinga
  68. Revestive Receives European Marketing Authorization for the Treatment ...

    Benzinga
  69. NPS Pharma Says Gattex Meeting October 16th

    Benzinga
  70. Biotechs With Upcoming PDUFA Dates

    Benzinga
  71. NPS Pharmaceuticals (NPSP) Gains 10.8% as Short Bowel Drug Moves ...

    MarketIntelligenceCenter
  72. Social Media Outlook for Friday June 22 (DRI, NPSP, R, GS)

    Benzinga
  73. Benzinga's Top Pre-Market Gainers

    Benzinga
  74. NPS Pharmaceuticals Reports NatparaTM Phase 3 Results to be Presented ...

    Benzinga
  75. NPS Pharmaceuticals Inc. Reports Operating Results (10-K)

    GuruFocus
  76. Benzinga's Top Pre-Market Gainers

    Benzinga
  77. Notable Call Options Activity in NPS Pharmaceuticals

    Benzinga
  78. Put Volume Surges on Plunging NPS Pharmaceuticals

    SchaeffersResearch
Trading Center